Cassava Sciences Files 8-K Report
Ticker: FLNA · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Cassava Sciences filed an 8-K for 'Other Events' - details pending.
AI Summary
On October 23, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not provided in the provided text. The company is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This filing signifies a material event has occurred for Cassava Sciences, Inc., requiring public disclosure. Investors should look for further details to understand the nature and impact of this event.
Risk Assessment
Risk Level: medium — The filing of an 8-K for 'Other Events' without immediate detail suggests a potentially significant development that could impact the company's stock.
Key Numbers
- 000-41905 — Commission File Number (Identifies the company's SEC filing history)
- 91-1911336 — I.R.S. Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Principal executive offices
- Pain Therapeutics Inc (company) — Former company name
FAQ
What specific 'Other Events' are being reported by Cassava Sciences, Inc. in this 8-K filing?
The provided text of the 8-K filing states 'Other Events' as an item information, but does not specify the nature of these events.
When was the earliest event reported in this filing?
The date of the earliest event reported is October 23, 2025.
What is Cassava Sciences, Inc.'s principal executive office address?
The principal executive offices are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What was Cassava Sciences, Inc.'s former company name?
The former company name was Pain Therapeutics Inc.
What is the SIC code for Cassava Sciences, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-24 08:10:05
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- sava20251024_8k.htm (8-K) — 24KB
- 0001437749-25-031674.txt ( ) — 154KB
- sava-20251023.xsd (EX-101.SCH) — 3KB
- sava-20251023_def.xml (EX-101.DEF) — 12KB
- sava-20251023_lab.xml (EX-101.LAB) — 15KB
- sava-20251023_pre.xml (EX-101.PRE) — 12KB
- sava20251024_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. Dismissal of Indictment of Dr. Hoau-Yan Wang On October 23, 2025, the United States District Court for the District of Maryland granted the United States' unopposed motion to dismiss with prejudice the criminal indictment against Hoau-Yan Wang, PhD. Dr. Wang is a former scientific collaborator and advisor to Cassava Sciences, Inc. ("Cassava" or the "Company") who conducted foundational research relating to the Company's investigational drug, simufilam. Among other things, the dismissed charges had accused Dr. Wang of causing Cassava to submit grant applications to the U.S. National Institutes of Health that allegedly contained false and fraudulent representations about his research and of manipulating or otherwise fabricating research results, including Western Blot images that he prepared. This order permanently terminates the case against Dr. Wang, and future charges related to the dismissed indictment cannot be refiled against Dr. Wang. Cassava Sciences recognizes and supports the critical importance of integrity in all forms of scientific research. The Company continues to move forward with its current program evaluating simufilam as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy based on research conducted at numerous institutions. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: October 24, 2025 By: /s/ ERIC J. SCHOEN Eric J. Schoen Chief Financial Officer